Celgene Co. (CELG) Holdings Trimmed by Webster Bank N. A.

Share on StockTwits

Webster Bank N. A. reduced its position in shares of Celgene Co. (NASDAQ:CELG) by 23.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 7,142 shares of the biopharmaceutical company’s stock after selling 2,248 shares during the quarter. Webster Bank N. A.’s holdings in Celgene were worth $458,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of CELG. Private Trust Co. NA increased its stake in Celgene by 2.2% in the fourth quarter. Private Trust Co. NA now owns 6,245 shares of the biopharmaceutical company’s stock worth $400,000 after purchasing an additional 132 shares during the period. Moody National Bank Trust Division increased its stake in Celgene by 0.6% in the fourth quarter. Moody National Bank Trust Division now owns 83,322 shares of the biopharmaceutical company’s stock worth $5,340,000 after purchasing an additional 487 shares during the period. Rehmann Capital Advisory Group increased its stake in Celgene by 6.4% in the third quarter. Rehmann Capital Advisory Group now owns 8,992 shares of the biopharmaceutical company’s stock worth $805,000 after purchasing an additional 544 shares during the period. Hills Bank & Trust Co. increased its stake in Celgene by 4.9% in the third quarter. Hills Bank & Trust Co. now owns 14,255 shares of the biopharmaceutical company’s stock worth $1,276,000 after purchasing an additional 672 shares during the period. Finally, Winslow Evans & Crocker Inc. increased its stake in Celgene by 7.0% in the third quarter. Winslow Evans & Crocker Inc. now owns 10,428 shares of the biopharmaceutical company’s stock worth $936,000 after purchasing an additional 680 shares during the period. Hedge funds and other institutional investors own 72.80% of the company’s stock.

Celgene stock opened at $87.51 on Thursday. The company has a debt-to-equity ratio of 4.06, a current ratio of 2.13 and a quick ratio of 1.99. Celgene Co. has a 52 week low of $58.59 and a 52 week high of $107.29. The stock has a market cap of $59.37 billion, a P/E ratio of 12.79, a PEG ratio of 0.43 and a beta of 1.44.

Celgene (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, October 25th. The biopharmaceutical company reported $2.29 earnings per share for the quarter, beating the consensus estimate of $2.02 by $0.27. The company had revenue of $3.89 billion during the quarter, compared to analysts’ expectations of $3.83 billion. Celgene had a return on equity of 108.76% and a net margin of 19.64%. On average, equities analysts anticipate that Celgene Co. will post 7.45 EPS for the current fiscal year.

A number of research firms have weighed in on CELG. Cantor Fitzgerald started coverage on Celgene in a research note on Monday, October 1st. They issued an “overweight” rating and a $100.00 target price on the stock. Zacks Investment Research lowered Celgene from a “buy” rating to a “hold” rating in a research note on Wednesday, September 26th. BidaskClub downgraded Celgene from a “buy” rating to a “hold” rating in a research report on Thursday, September 13th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Celgene in a research report on Thursday, October 11th. Finally, Canaccord Genuity downgraded Celgene from a “buy” rating to a “hold” rating in a research report on Thursday, January 3rd. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $111.78.

TRADEMARK VIOLATION WARNING: “Celgene Co. (CELG) Holdings Trimmed by Webster Bank N. A.” was first published by Zolmax and is the sole property of of Zolmax. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://zolmax.com/investing/celgene-co-celg-holdings-trimmed-by-webster-bank-n-a/2816096.html.

About Celgene

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Recommended Story: Earnings Per Share (EPS) Explained

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Costco Wholesale Co. Shares Rise 0% Following  December Same-Store Sales Report
Costco Wholesale Co. Shares Rise 0% Following December Same-Store Sales Report
Old National Bancorp  Shares Gap Down  After Earnings Miss
Old National Bancorp Shares Gap Down After Earnings Miss
New Oriental Education & Tech Grp  Shares Up 7.8% on Strong Earnings
New Oriental Education & Tech Grp Shares Up 7.8% on Strong Earnings
Traders Purchase Large Volume of Call Options on Wisdom Tree Investments
Traders Purchase Large Volume of Call Options on Wisdom Tree Investments
Investors Purchase High Volume of Varian Medical Systems Put Options
Investors Purchase High Volume of Varian Medical Systems Put Options
Sherwin-Williams  Scheduled to Post Earnings on Thursday
Sherwin-Williams Scheduled to Post Earnings on Thursday


Leave a Reply

 
© 2006-2019 Zolmax.